GlaxoSmithKline and Galapagos have expanded their arthritis alliance to include additional drug discovery programs based on novel drug target GT622. Galapagos will receive a payment from GSK of $10 million in cash and becomes eligible for additional success-based milestones and royalties. Since the start of the alliance in June 2006, Galapagos has received a $62million in payments from GSK. The expanded arthritis alliance with GSK is now worth more than $300 million in milestones, in addition to...